Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
The combination of estrogen and fluoxetine refers to the co-administration of estrogenic hormones (such as estradiol or conjugated estrogens) and the selective serotonin reuptake inhibitor (SSRI) fluoxetine. This therapeutic strategy is primarily investigated for the management of vasomotor symptoms (hot flashes) and mood disturbances associated with menopause, perimenopause, and Premenstrual Dysphoric Disorder (PMDD). Estrogen acts as an agonist at estrogen receptors to stabilize thermoregulation and maintain bone density, while fluoxetine increases synaptic serotonin levels by inhibiting the serotonin transporter (SERT), thereby alleviating depressive and anxiety symptoms. While both components are individually FDA-approved, they are typically prescribed as separate agents rather than a fixed-dose combination product.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on estrogen + fluoxetine.